Institution
Children's Memorial Hospital
Healthcare•
About: Children's Memorial Hospital is a based out in . It is known for research contribution in the topics: Population & Transplantation. The organization has 5652 authors who have published 8967 publications receiving 283837 citations.
Topics: Population, Transplantation, Medicine, Poison control, Health care
Papers published on a yearly basis
Papers
More filters
TL;DR: This chapter will review the research data on the epidemiology, clinical presentation and treatment approaches for sleep disorders frequently seen in the context of common psychiatric conditions in children and adolescents.
99 citations
TL;DR: Findings of congenital and acute acquired ocular toxoplasmosis include retinal scars, white-appearing lesions in the active phase often associated with vitritis, and fibrous bands, secondary serous or rhegmatogenous retinal detachments, optic neuritis and neuropathy, cataracts, and choroidal neovascular membranes are reviewed.
Abstract: Clinical manifestations of ocular toxoplasmosis are reviewed. Findings of congenital and acute acquired ocular toxoplasmosis include retinal scars, white-appearing lesions in the active phase often associated with vitritis. Complications can include fibrous bands, secondary serous or rhegmatogenous retinal detachments, optic neuritis and neuropathy, cataracts, increased intraocular pressure during active infection, and choroidal neovascular membranes. Recurrences in untreated congenital toxoplasmosis occur in teenage years. Manifestations at birth are less severe, and recurrences are fewer in those who were treated promptly early in the course of their disease in utero and in the first year of life. Severe retinal involvement is common at diagnosis of symptomatic congenital toxoplasmosis in the United States and Brazil. Acute acquired infections also may be complicated by toxoplasmic retinochoroiditis, with recurrences most common close to the time of acquisition. Suppressive treatment can reduce recurrent disease.
99 citations
University of California, San Diego1, Boston Children's Hospital2, Morgan Stanley Children's Hospital3, Johns Hopkins University4, Saint Louis University5, Cincinnati Children's Hospital Medical Center6, Baylor College of Medicine7, Emory University8, Indiana University9, Children's Memorial Hospital10, University of California, San Francisco11, University of Washington12, Washington University in St. Louis13, National Institutes of Health14
TL;DR: It is found that 1 year of CBDR did not reduce overall histologic markers of NAFLD compared with placebo in children, and those taking CBDR had a 4-fold better chance of histologic improvement.
99 citations
RTI International1, University of North Carolina at Chapel Hill2, Cincinnati Children's Hospital Medical Center3, Tel Aviv University4, Broad Institute5, Harvard University6, Georgia Institute of Technology7, Children's Hospital of Eastern Ontario8, Nationwide Children's Hospital9, University of Toronto10, Boston Children's Hospital11, Emory University12, University of Pittsburgh13, Women & Children's Hospital of Buffalo14, University of Pennsylvania15, University of Texas Southwestern Medical Center16, Izaak Walton Killam Health Centre17, University of California, San Francisco18, Medical College of Wisconsin19, Johns Hopkins University20, Children's Memorial Hospital21, University of California, Los Angeles22, Primary Children's Hospital23, University of Minnesota24, Icahn School of Medicine at Mount Sinai25, State University of New York Upstate Medical University26, Vanderbilt University27, Nemours Foundation28, National Institutes of Health29, Massachusetts Institute of Technology30
TL;DR: The findings support the utility of initial clinical activity and treatment response by 4 weeks to predict week 52 corticosteroid-free remission with mesalazine alone in children who are newly diagnosed with ulcerative colitis.
98 citations
Roswell Park Cancer Institute1, University at Buffalo2, University of Washington3, Fred Hutchinson Cancer Research Center4, University of Southern California5, Northwestern University6, City of Hope National Medical Center7, University of Texas Health Science Center at Houston8, Boston Children's Hospital9, University of Alberta10, University of Pennsylvania11, Loma Linda University12, Harvard University13, Rowan University14, Indiana University – Purdue University Indianapolis15, University of Calgary16, Louisiana State University17, University of Nebraska–Lincoln18, Children's Memorial Hospital19, Cleveland Clinic20, University of Texas Southwestern Medical Center21, University of Texas MD Anderson Cancer Center22, University of California, San Diego23
TL;DR: NWTS‐5 was a multi‐institutional clinical trial for patients less than 16 years of age at diagnosis with specific renal neoplasms who were diagnosed between August 1, 1995 and May 31, 2002.
Abstract: Purpose
NWTS-5 was a multi-institutional clinical trial for patients less than 16 years of age at diagnosis with specific renal neoplasms who were diagnosed between August 1, 1995 and May 31, 2002. A uniform approach to the treatment of patients with relapse was employed.
Patients and Methods
Seventy-two patients who relapsed after immediate nephrectomy (stages I and II), initial chemotherapy with vincristine (VCR) and actinomycin D and no radiation therapy were registered on stratum B of the NWTS-5 relapse protocol. Four patients were not evaluable: one due to insufficient data and three due to major protocol violations. Among the 68 remaining patients, one who was 19 years of age at initial diagnosis of Wilms tumor, five with bilateral Wilms tumor at diagnosis, three who developed a contralateral relapse, and one with persistent disease were not included in this analysis. Relapse treatment included surgical excision, when feasible, radiation therapy and alternating courses of VCR, doxorubicin and cyclophosphamide and etoposide and cyclophosphamide.
Results
The outcomes of 58 patients were analyzed. The lung was the only site of relapse for 31 patients. Event-free survival 4 years after relapse was 71.1% and 4-year overall survival was 81.8% for all patients and were 67.8 and 81.0% for those who relapsed only to their lungs. The most frequent toxicities were hematological.
Conclusions
These results demonstrate that a significant proportion of children with Wilms tumor who relapse after initial treatment with VCR and actinomycin D can be successfully re-treated. Pediatr Blood Cancer 2007;48:493–499. © 2006 Wiley-Liss, Inc.
98 citations
Authors
Showing all 5672 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Jorge E. Cortes | 163 | 2784 | 124154 |
| Marc C. Hochberg | 127 | 691 | 87268 |
| Michael Andreeff | 117 | 959 | 54734 |
| Bharat Bhushan | 116 | 1276 | 62506 |
| Donald M. Lloyd-Jones | 115 | 706 | 112655 |
| David N. Herndon | 108 | 1227 | 54888 |
| Frederick J. Schoen | 102 | 434 | 42611 |
| Kathryn M. Edwards | 102 | 628 | 39467 |
| Alan R. Dyer | 95 | 283 | 44252 |
| Mark C. Willingham | 94 | 394 | 36167 |
| Nicholas Katsanis | 93 | 348 | 34133 |
| Peter D. Gluckman | 92 | 525 | 33375 |
| Helga Refsum | 90 | 316 | 37463 |
| Dale A. Schoeller | 90 | 391 | 30776 |
| Shlomo Shinnar | 90 | 288 | 25621 |